ClinicalTrials.gg
TerminatedNCT00508157Updated Nov 12, 2026Results posted

A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome

A Phase 4 interventional study of Aripiprazole and Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine) in Metabolic Syndrome and Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 30 sites in 9 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment

How we know

Why this study was terminated
Slow Accrual
Updated Nov 12, 2026Posted results revisedSponsor changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing aripiprazole in Metabolic Syndrome — none open to participants now, none under way, none of them phase 3. Aripiprazole · Metabolic Syndrome.

Enrollment
4th of 10
125 · median 57
Started
2007
with 1 other
Phase 4
6 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
2 of 10
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 10 studies testing aripiprazole in Metabolic Syndrome, this one is the 4th largest by enrollment, is one of 2 that started in 2007, is one of 6 in phase 4, and was the 4th registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

None of the 10 studies testing aripiprazole in Metabolic Syndrome is open now. The open studies under Metabolic Syndrome, anywhere →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing aripiprazole in Metabolic Syndrome as a file.
02

Study summary

258 patients who have been treated for at least 3 months with oral olanzapine, risperidone or quetiapine in the treatment of schizophrenia and currently presenting with metabolic syndrome, will be randomized to: i) aripiprazole for 16 weeks, with flexible dosing within a range of 10 to 30 mg once daily (QD); or ii) continue for 16 weeks on the same atypical antipsychotic treatment prior to the study enrollment.

03

Conditions studied

  • Metabolic Syndrome
  • Schizophrenia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Patients:

  • with schizophrenia being treated with olanzapine, risperidone, or quetiapine for at least 3 months
  • with diagnosis of metabolic syndrome
  • not treated for 1 of the parameters of metabolic syndrome
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    A

    Drug: Aripiprazole

  • Active comparator
    B

    Drug: Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)

Interventions

  • Tablets, Oral, 5 to 30 mg, once daily, 16 weeks

    Also known as: Abilify, BMS-337039

  • DrugContinued Antipsychotic (Risperidone or Quetiapine or Olanzapine)

    Tablets, Oral, According to summary of product characteristics (SmPC)

06

What researchers measure

Primary outcomes

  1. Mean Percent Change From Baseline in Fasting Non-high Density Lipoprotein (HDL) Cholesterol at Week 16

    Non-HDL cholesterol was calculated as fasting Total Cholesterol minus fasting HDL Cholesterol.

    Time frame: Baseline, Week 16

Secondary outcomes

  1. Number of Participants Remaining on Metabolic Syndrome at Week 16

    Metabolic syndrome is defined as the presence of at least 3 out of the following Adult Treatment Panel III-A (ATP III-A) criteria (all of which are to be assessed at the same visit): waist \>102 cm in males, \>88 cm in females; blood pressure (BP) systolic BP ≥130 or diastolic BP ≥85 mm Hg; fasting HDL \<40 mg/dL in males, \<50 mg/dL in females; fasting triglycerides ≥150 mg/dL; fasting glucose ≥100 mg/dL, and/or the start of a treatment for any of the parameters of metabolic syndrome during the course of the study.

    Time frame: Week 16

  2. Mean Percent Change From Baseline in Fasting Lipid Parameters Through Week 16

    Mean percent change from baseline in total cholesterol, low-density lipoprotein (LDL), HDL, and triglycerides.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16

  3. Mean Change From Baseline for Fasting Glucose Levels Through Week 16

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16

  4. Mean Change From Baseline in Body Weight Through Week 16

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16

  5. Median Change From Baseline in Body Mass Index (BMI) Through Week 16

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16

  6. Mean Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale Through Week 16

    A CGI-S assessment (a 7-point scale to evaluate the severity of symptoms) was performed at baseline (1=normal; 7=among the most extremely ill patients). A decrease in value indicates improvement.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16

  7. Mean Change From Baseline in Subjective Well-Being Under Neuroleptics Scale (SWN-short Form) Through Week 16

    The SWN-short form is a 20-item self-report instrument that measures subjective well-being under neuroleptics. 10 positive and 10 negative items cover 5 health domains (subscales) (4 items each): emotional regulation, self-control, mental functioning, social integration, and physical functioning. Individual scores range from 1 (not at all) to 6 (very much). With negative item scores being reversed, Subscale scores range from 4 to 24 and Total score ranges from 20 to 120.

    Time frame: Baseline, Week 4, Week 8,Week 12, Week 16

  8. Mean Change From Baseline in the Impact of Weight on Quality of Life (IWQoL-Lite) Scale Through Week 16

    IWQoL-Lite is a 31-item self-report inventory to assess the impact of weight on quality of life among patients with obesity. Subscales include: Physical Function, Self Esteem, Sexual Life, Public Distress and Work. The rescaled IWQoL-Lite Total Score is determined by the sum of the 1 to 5 scores on all 31 items and rescaling this sum to a 0-100 scoring with 0=the poorest and 100=the best quality of life. A change of 7.8 to 12.0 points on the rescaled IWQoL-Lite Total Score=a meaningful improvement. A change of -4.5 to -7.6 on the rescaled IWQoL-Lite Total Score=a meaningful deterioration.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16

07

Results

Posted Jul 20, 2010
Limitations and caveats
Following a review of all studies in development, a strategic decision was made to terminate this study due to slow accrual. Patients randomized and treated at the time of study termination could continue the study as per protocol until completion.

Participant flow

Participant flow — Overall Study
MilestoneControl GroupAripiprazole
Started2626
Randomized sample2626
Safety sample2625
Completed2423
Not completed23
Withdrew: Adverse event01
Withdrew: Subject withdrew consent10
Withdrew: Lost to follow-up10
Withdrew: Subject no longer met study criteria01
Withdrew: Other known cause01

Outcome measures

PrimaryMean Percent Change From Baseline in Fasting Non-high Density Lipoprotein (HDL) Cholesterol at Week 16

Non-HDL cholesterol was calculated as fasting Total Cholesterol minus fasting HDL Cholesterol.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Mean Percent Change From Baseline in Fasting Non-high Density Lipoprotein (HDL) Cholesterol at Week 16
percent changeControl GroupAripiprazole
Mean Percent Change From Baseline in Fasting Non-high Density Lipoprotein (HDL) Cholesterol at Week 1610.06 ± 4.35-2.3 ± 3.85
Statistical analysis
  • Control Group vs Aripiprazole · ANCOVA · Mean difference (final values): -11.28 · 95% CI -19.14 to -2.66Relative difference of Aripiprazole vs. Control Group in terms of (mean % change from baseline/100)+1.
SecondaryNumber of Participants Remaining on Metabolic Syndrome at Week 16

Metabolic syndrome is defined as the presence of at least 3 out of the following Adult Treatment Panel III-A (ATP III-A) criteria (all of which are to be assessed at the same visit): waist \>102 cm in males, \>88 cm in females; blood pressure (BP) systolic BP ≥130 or diastolic BP ≥85 mm Hg; fasting HDL \<40 mg/dL in males, \<50 mg/dL in females; fasting triglycerides ≥150 mg/dL; fasting glucose ≥100 mg/dL, and/or the start of a treatment for any of the parameters of metabolic syndrome during the course of the study.

Time frame:
Week 16
Reported as:
Number · participants
Number of Participants Remaining on Metabolic Syndrome at Week 16
participantsControl GroupAripiprazole
Number of Participants Remaining on Metabolic Syndrome at Week 162216
Statistical analysis
  • Control Group vs Aripiprazole · Cochran-Mantel-Haenszel · Risk ratio (rr): 0.76 · 95% CI 0.54 to 1.06A relative risk \< 1 favors Aripiprazole over Control Group.
SecondaryMean Percent Change From Baseline in Fasting Lipid Parameters Through Week 16

Mean percent change from baseline in total cholesterol, low-density lipoprotein (LDL), HDL, and triglycerides.

Time frame:
Baseline, Week 4, Week 8, Week 12, Week 16

No measurements were reported for this outcome.

SecondaryMean Change From Baseline for Fasting Glucose Levels Through Week 16
Time frame:
Baseline, Week 4, Week 8, Week 12, Week 16

No measurements were reported for this outcome.

SecondaryMean Change From Baseline in Body Weight Through Week 16
Time frame:
Baseline, Week 4, Week 8, Week 12, Week 16

No measurements were reported for this outcome.

SecondaryMedian Change From Baseline in Body Mass Index (BMI) Through Week 16
Time frame:
Baseline, Week 4, Week 8, Week 12, Week 16

No measurements were reported for this outcome.

SecondaryMean Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale Through Week 16

A CGI-S assessment (a 7-point scale to evaluate the severity of symptoms) was performed at baseline (1=normal; 7=among the most extremely ill patients). A decrease in value indicates improvement.

Time frame:
Baseline, Week 4, Week 8, Week 12, Week 16

No measurements were reported for this outcome.

SecondaryMean Change From Baseline in Subjective Well-Being Under Neuroleptics Scale (SWN-short Form) Through Week 16

The SWN-short form is a 20-item self-report instrument that measures subjective well-being under neuroleptics. 10 positive and 10 negative items cover 5 health domains (subscales) (4 items each): emotional regulation, self-control, mental functioning, social integration, and physical functioning. Individual scores range from 1 (not at all) to 6 (very much). With negative item scores being reversed, Subscale scores range from 4 to 24 and Total score ranges from 20 to 120.

Time frame:
Baseline, Week 4, Week 8,Week 12, Week 16

No measurements were reported for this outcome.

SecondaryMean Change From Baseline in the Impact of Weight on Quality of Life (IWQoL-Lite) Scale Through Week 16

IWQoL-Lite is a 31-item self-report inventory to assess the impact of weight on quality of life among patients with obesity. Subscales include: Physical Function, Self Esteem, Sexual Life, Public Distress and Work. The rescaled IWQoL-Lite Total Score is determined by the sum of the 1 to 5 scores on all 31 items and rescaling this sum to a 0-100 scoring with 0=the poorest and 100=the best quality of life. A change of 7.8 to 12.0 points on the rescaled IWQoL-Lite Total Score=a meaningful improvement. A change of -4.5 to -7.6 on the rescaled IWQoL-Lite Total Score=a meaningful deterioration.

Time frame:
Baseline, Week 4, Week 8, Week 12, Week 16

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole—0/25 (0%)9/25 (36%)
Control Group—0/26 (0%)2/26 (7.7%)
Most frequent other events
Most frequent other events
EventAripiprazoleControl Group
HeadacheNervous system disorders4/250/26
AnxietyPsychiatric disorders3/250/26
InsomniaPsychiatric disorders3/250/26
NauseaGastrointestinal disorders3/250/26
RashSkin and subcutaneous tissue disorders2/250/26
Blood cholesterol increasedInvestigations0/252/26

Baseline characteristics

Age, Continuous
Age, Continuous(years)Control GroupAripiprazoleTotal
Mean40.7 ± 10.4743.9 ± 11.1642.3 ± 10.84
Sex: Female, Male
Sex: Female, Male(Participants)Control GroupAripiprazoleTotal
Female131124
Male131528
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Control GroupAripiprazoleTotal
White232649
Black/African American101
Asian101
Other101
Body Mass Index (BMI) category
Body Mass Index (BMI) category(Participants)Control GroupAripiprazoleTotal
< 30 kg/m271320
>=30 kg/m2191332
Waist Circumference Category
Waist Circumference Category(participants)Control GroupAripiprazoleTotal
≤ 102 cm for Men/ ≤ 88 cm for Women123
> 102 cm for Men/ > 88 cm for Women252449
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m2)Control GroupAripiprazoleTotal
Mean31.45 (19.0 to 42.8)31.31 (25.1 to 49.1)31.38 (19.0 to 49.1)
Fasting Non-High Density Lipoprotein (HDL) Cholesterol
Fasting Non-High Density Lipoprotein (HDL) Cholesterol(mg/dL)Control GroupAripiprazoleTotal
Mean173.1 (118 to 267)169.0 (110 to 268)171.0 (110 to 268)
Waist Circumference
Waist Circumference(cm)Control GroupAripiprazoleTotal
Mean107.1 (90 to 136)107.1 (91 to 134)107.1 (90 to 136)

1 further baseline measures are reported on the registry.

08

Study locations

30 sites
  • Local Institution
    Brussels, 1160, Belgium
  • Local Institution
    Brno, 602 00, Czechia
  • Local Institution
    Brno, 625 00, Czechia
  • Local Institution
    Havířov, 736 01, Czechia
  • Local Institution
    Hradec Králové, 500 05, Czechia
  • Local Institution
    Prague, 100 00, Czechia
  • Local Institution
    Prague, 160 00, Czechia
  • Local Institution
    Prague, 190 00, Czechia
  • Local Institution
    Přerov, 750 02, Czechia
  • Local Institution
    Roudnice nad Labem, 41301, Czechia
  • Local Institution
    Fains-Véel, 55000, France
  • Local Institution
    Lille, 59037, France
  • Local Institution
    Limoges, 87025, France
  • Local Institution
    Montpellier, 34295, France
  • Local Institution
    Paris, 75013, France
  • Local Institution
    Paris, 75674, France
  • Local Institution
    Poitiers, 86000, France
  • Local Institution
    Strasbourg, 67000, France
  • Local Institution
    Ellwangen, 73479, Germany
  • Local Institution
    Werneck, 97440, Germany
  • Local Institution
    Chania-Crete, 73300, Greece
  • Local Institution
    Corfu, 49100, Greece
  • Local Institution
    Budapest, 1125, Hungary
  • Local Institution
    Gyula, 5700, Hungary
  • Local Institution
    Oviedo, Principality of Asturias 33011, Spain
  • Local Institution
    Barcelona, 08025, Spain
  • Local Institution
    Barcelona, 08036, Spain
  • Local Institution
    Barcelona, 08907, Spain
  • Local Institution
    Wetzikon, 8620, Switzerland
  • Local Institution
    Izmir, 35370, Turkey (Türkiye)
09

References and documents

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2007 to primary completion in Mar 2009, 16 months.

Results were first posted in Jul 2010, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2007
First posted
Jul 27, 2007
StartActual
Nov 1, 2007
Primary completionActual
Mar 1, 2009
CompletionActual
Mar 1, 2009
Results first posted
Jul 20, 2010
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Nov 12, 2026
Sites
11 sites added, 11 sites removed
Show 11 added (6 Czechia, 4 France, 1 Spain)
  • Local Institution · Havířov, Czechia
  • Local Institution · Hradec Králové, Czechia
  • Local Institution · Prague, Czechia
  • Local Institution · Prague, Czechia
  • Local Institution · Přerov, Czechia
  • Local Institution · Roudnice nad Labem, Czechia
  • Local Institution · Fains-Véel, France
  • Local Institution · Lille, France
  • Local Institution · Limoges, France
  • Local Institution · Paris, France
  • Local Institution · Oviedo, Spain
Show 11 removed
  • Local Institution · Havirov, Czech Republic
  • Local Institution · Hradec Kralove, Czech Republic
  • Local Institution · Praha 10, Czech Republic
  • Local Institution · Praha 6, Czech Republic
  • Local Institution · Prerov, Czech Republic
  • Local Institution · Roudnice Nad Labem, Czech Republic
  • Local Institution · Fains Veel, France
  • Local Institution · Lille Cedex, France
  • Local Institution · Limoges Cedex, France
  • Local Institution · Paris Cedex 14, France
  • Local Institution · Oviedo, Spain
Nov 12, 2026
Sponsor
Bristol-Myers Squibb→Otsuka Pharmaceutical Development & Commercialization, Inc.
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Posted results revised
    11 sites added, 11 sites removed
    Show 11 added (6 Czechia, 4 France, 1 Spain)
    • Local Institution · Havířov, Czechia
    • Local Institution · Hradec Králové, Czechia
    • Local Institution · Prague, Czechia
    • Local Institution · Prague, Czechia
    • Local Institution · Přerov, Czechia
    • Local Institution · Roudnice nad Labem, Czechia
    • Local Institution · Fains-Véel, France
    • Local Institution · Lille, France
    • Local Institution · Limoges, France
    • Local Institution · Paris, France
    • Local Institution · Oviedo, Spain
    Show 11 removed
    • Local Institution · Havirov, Czech Republic
    • Local Institution · Hradec Kralove, Czech Republic
    • Local Institution · Praha 10, Czech Republic
    • Local Institution · Praha 6, Czech Republic
    • Local Institution · Prerov, Czech Republic
    • Local Institution · Roudnice Nad Labem, Czech Republic
    • Local Institution · Fains Veel, France
    • Local Institution · Lille Cedex, France
    • Local Institution · Limoges Cedex, France
    • Local Institution · Paris Cedex 14, France
    • Local Institution · Oviedo, Spain
    Sponsor Bristol-Myers Squibb→Otsuka Pharmaceutical Development & Commercialization, Inc.
    + 5 other changes: identifiers, verification date, date precision, contact details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT00508157
Responsible party
Sponsor
First posted
Jul 27, 2007
Start date
Nov 1, 2007
Primary completion
Mar 1, 2009
Completion
Mar 1, 2009
Results posted
Jul 20, 2010
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion